Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAAR: SoluMatrix Abiraterone vs Zytiga in mCRPC
NCT02737332Phase 2Completed
- Sponsor
- Sun Pharma
- Start
- Mar 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Abiraterone Acetate Tablets (I) in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Sun Pharma. Primary endpoint: Serum Testosterone Levels at Day 10. Started Mar 2016; status: completed.
02
Drugs
Abiraterone Acetate Tablets (I)
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02737332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02737332.